Sunday, May 22, 2016

What is going on with Falco.......


For about a year and 1/2 now I've been following this great company (HERE) and it finally seems like the market is taking notice.

For those who have forgotten or don't know the details, I suggest you read these older articles:

Could This Be Canada’s Next Big Discovery?

Is This the Next Osisko?

Is Osisko Gold Royalties charting a new course for Falco Resources?

Falco Shooting For 5 Million Oz. By Year End


The complete OSISKO team has taken over: news here
Same guys that founded, built and sold Canadian Malartic for $3.9 Billion
Same guys that are calling Falco, Canadian Malartic 2.0

Osisko Gold Royalties have moved from 10% ownership to 19.9%: news here

Updated Horne 5 resources estimate in Jan 2016: news here

5.36 Million oz AuEq Indicated

1.25 Million oz AuEq Inferred

Releases Horne 5 PEA earlier this month: news here

--  NPV of $1,131 million at a 5% discount rate and an IRR of 20.0% before
    taxes and mining duties
--  NPV of $667 million at a 5% discount rate and an IRR of 16.0% after
    taxes and mining duties
--  Top Quartile Project at All-In Sustaining Costs of US$427/oz Au, net of
    By-Product Credits
--  All-In Cost (CAPEX plus OPEX) at US$660/oz Au
Will be interesting to see what happens next....but with a market cap of $89 million, an after tax NPV of $667 million and recent buyout of Kaminak for $520 million by Goldcorp...Falco share price has some major catching up to do.


20,000 meters, divided in 10,000 meters at Horne 5 and 10,000 meters at Quemont.

Falco Resources FPC Horne 2

Falco Resources (FPC.V) has been quiet for a while, but earlier this week the company announced it was mobilizing two drill rigs to start a new surface drill program at the Horne 5 mine in Québec, Canada. Falco is planning to drill a total of 20,000 meters, divided in 10,000 meters at Horne 5 and 10,000 meters at Quemont.
Falco Resources FPC Horne 1
At Quemont, the company will follow up on the western plunge of the historic deposit where 3.2 million ounces of gold and almost 15 million ounces of silver have been produced. The average grade of the historic production at Quemont was very high at 6.5 g/t gold, 1.3% copper, 30.8 g/t silver and 2.4% zinc. Using today’s spot prices (and not taking the different recovery rates into account) this would be a gold-equivalent grade of just in excess of 9.6 g/t.
At Horne 5, Falco is planning to drilla total of 10 holes consisting of 7 wedges and 3 pilot holes, targeting a mineralized structure located at a depth of 600-1,200 meters below surface. This drill program will follow up on and try to extend the excellent results from the 2015 drill program where the company discovered 34 meters at 3.4 g/t AuEq. Should the drill program prove to be successful, there’s no reason why this couldn’t result in an updated (and expanded) resource estimate for the total Horne 5 mine.

Friday, May 13, 2016


(TSXV: NX) (2NKN: Frankfurt) (the “Company” or “Noka”) is pleased to announce that it has entered into an option agreement with arms' length optionors to acquire a 100% interest in the Lincoln Lithium Project (the “Lincoln Property”) located in the Clayton Valley area of west central Nevada.
Location and Tenure
The Lincoln Property consists of approximately 3500 acres located in northwest part of the prolific Clayton Valley. The Lincoln Property is situated near the northwest flank of Rockwood Lithium’s Silver Peak mine, the only lithium producer in North America. This exciting new prospect lies adjacent to the west of Lithium X’s north block. Exploration logistics are excellent with property access via a paved highway approximately ½ km from the property boundary.
Location Map

Historic Work in Clayton Valley
In the 1970’s, the United States Geological Services (“USGS”) conducted a 7 hole drill program along the north end of the Clayton Valley in an effort to identify lithium bearing brines and volcanic sediments. All of the holes reported anomalous lithium with grades ranging from 310 ppm to 1700 ppm and as shallow as 100 feet (30 meters). The Lincoln Property lies within 500 meters of one of the seven USGS holes, one of the holes reports as high as 930 ppm lithium at a depth of 100 feet (30 meters). (Source: USGS Open-File Report 82-415, 1982)
Currently Rockwood Lithium extracts and processes lithium bearing brines. This mine has been supplying the lithium market since 1967. Other active companies in the Valley include Pure Energy, 9km south of Lincoln with a current NI 43-101 inferred resource of 816,000 tons. Also Lithium X has recently been approved for drilling on their north block, adjacent to the Lincoln Property. (Lithium X Press Release 03-23-2016)

Wednesday, May 11, 2016

RHT or FLNTF: Reliq wins $1.22M (U.S.) health service software deal

2016-05-11 16:42 ET - News Release

Dr. Lisa Crossley reports

Reliq Health Technologies Inc. has signed a contract with NextGen Partners LLC of San Antonio, Tex., valued at $1.22-million (U.S.). The contract provides NextGen with professional services and a limited licence to Reliq's proprietary iUGO Health platform (formerly known as CareKit Health), specifically for the development of a consumer-focused mobile health app (Mindful Health App) that will be provided to the residents of San Antonio, Tex.

Under the terms of the agreement with NextGen, the company will receive an upfront payment of $450,000 (U.S.).

"We are excited to be part of NextGen's initiative to improve health outcomes and enhance access to care," said Dr. Lisa Crossley, chief executive officer of Reliq Health. "Our virtual care platform uses a high-tech, low-touch approach to provide high-quality healthcare in the home while reducing the cost of care delivery. Working in conjunction with NextGen Partners, we will be able to leverage our existing platform to create a customized mobile health app that will allow the residents of San Antonio to proactively manage their own health."

"NextGen's partnership with Reliq Health will allow us to leverage their existing mHealth platform to provide a novel, innovative mobile healthcare solution to the citizens of San Antonio and surrounding area," said a spokesperson of NextGen Partners. "The resulting Mindful Health mobile app will provide a telemedicine platform that connects patients to doctors and nurses anywhere where there is internet access. Mindful Health will support secure video consults for patients with doctors and nurses, providing patients with professional care from the comfort of their own home. The Mindful Health app will also provide automated prescription refills, search tools for healthcare services, a personalized health calendar with push notifications, reminders, and a suite of billing and payment tools. Mindful Health will provide greater access to healthcare, while at the same time reducing healthcare costs."

The city of San Antonio, Tex., is the seventh most populated city in the United States and the second most populated city in Texas, with a population of over 1.4 million residents.

We seek Safe Harbor.

Saturday, April 9, 2016

Breath Analysis — The Future of Disease Detection

Image result for breathtec biomedical


What can be detected in the blood can be detected in the breath

Anything in your body that is eventually in the blood can be measured in your breath, and diseases all have a distinctive signature which can be distinguished using breath analysis.
Breathtec Biomedical aims to advance breath analysis technology for the early screening of life-threatening diseases.  Non-invasive & Non-intrusive: Unlike current lab testing alternatives, a breath test can be conducted almost anywhere, anytime.

Tuesday, December 1, 2015


Moseda Technologies Inc. has received a second purchase ordering totalling over $250,000 from an existing client for software and hardware. The client is servicing a company in the home care market with over 50,000 patients.

"This reoccurring business demonstrates the growing need for both hardware and software that allows for the implementation of mHealth and telemedicine initiatives. We are witnessing first hand the growing demand from various home care and long-term care providers for innovative technologies that have the potential to enhance the delivery of care and and increase operational efficiencies," said Nick Murray, chief executive officer of Moseda. "We look forward to rolling out additional implementations as we ramp up our sales efforts."

As a part of the company's growth strategy it is currently looking to expand its business development and sales team in order to reach more clients throughout North America. The company has also begun exploring Asia as a market for its technologies and has commenced talks with three potential partners to potentially deliver them a telemedicine solution. Further updates will be provided as required.

We seek Safe Harbor.

Thursday, October 15, 2015

Moseda Technologies Announces $350,000 Purchase Order from Health Care Client

VANCOUVER, BRITISH COLUMBIA, Oct 15, 2015 (Marketwired via COMTEX) -- Moseda Technologies Inc. (MSD) ("Moseda" or the "Company"), a technology company focused on developing progressive mobile health (the "mHealth") and telemedicine solutions for institutional and home healthcare, is pleased to announce that the Company has received an initial purchase order totalling over CAD $350,000 from an unnamed client for software and hardware. The client is servicing a company in the home care space with over 20,000 patients. The order will be delivered and implemented in full by the end of November.
"We are excited to be servicing this client in the health care space. The transaction validates the demand for technologies that allow for the implementation of effective mHealth and telemedicine initiatives," said Nicholas Murray, CEO of Moseda. "Progressive health care companies and providers are seeking out technologies such as ours. We look forward to providing them with state of the art hardware and software that are specifically designed to ensure cost efficacy and improve patient care."
The home care and long-term care market in North America is estimated to be $137 billion annually according to
Nicholas Murray,CEO & Director

Thursday, October 8, 2015

Moseda Technologies Announces Distribution Agreement With a Top 10 Pharma and Diagnostics Company

VANCOUVER, BRITISH COLUMBIA, Oct 08, 2015 (Marketwired via COMTEX) -- Moseda Technologies Inc. (MSD) ("Moseda" or the "Company"), a technology company focused on developing progressive mobile health (the "mHealth") and telemedicine solutions for institutional and home healthcare, is pleased to announce that the Company has signed a distribution agreement (the "Agreement") with a top 10, multi-national pharma and diagnostics company.
The Agreement appoints Moseda as a distributor of products in Canada. Pricing for the subject products is negotiated and may be updated once per year, on January 1st. In the event of price changes a minimum of 60 days advance notice will be provided to Moseda.
"We are excited to introduce these products to our target markets in pharmacy, long term care, retirement homes and home care. Offering a tried and tested product from a trusted and globally recognized name will allow us to better serve existing customers and further expand the adoption of our mHealth and telemedicine applications in the market," said Nicholas Murray, CEO of Moseda.
The Company plans to launch sales in Q4-2015.
Nicholas Murray, CEO & Director

Tuesday, October 6, 2015

Fantasy Sports Corp starts trading on the TSXV

Symbol FAS

2015-10-05 20:35 ET - New Listing

See Change Name (C-DTS) DraftTeam Daily Fantasy Sports Corp
Pursuant to a resolution passed by shareholders on Sept. 30, 2015, the company has changed its name to Fantasy Aces Daily Fantasy Sports Corp. There is no consolidation of capital.

Effective at the opening on Tuesday, Oct. 6, 2015, the common shares of Fantasy Aces Daily Fantasy Sports will commence trading on the TSX Venture Exchange, and the common shares of DraftTeam Daily Fantasy Sports Corp. will be delisted. The company is classified as a technology company.

Capitalization:  unlimited shares with no par value, of which 80,809,161 shares are issued and outstanding

Escrow:  1,387,745 shares are subject to 36-month staged release escrow, all of which are subject to a Tier 2 value security escrow agreement

Escrow:  57,539,453 DraftTeam LP convertible units are subject to 36-month staged release escrow, all of which are subject to a Tier 2 value security escrow agreement

Transfer agent:  Valiant Trust Company

Trading symbol:  FAS (new)

Cusip No.:  307292 10 2 (new)


Wednesday, September 30, 2015

Moseda Technologies Announces Health Canada Approval for Medical Device Establishment License

Moseda Technologies Inc. has been issued a medical device establishment licence (licence No. 6711) by Health Canada. The licence allows the company to import Class 3 medical devices and distribute them within Canada.

"Obtaining a medical device establishment licence is one of the key steps towards adoption of our health care software. The ability to access software market share through the sale of already commercialized devices is a major component of our go-to-market strategy," said Nicolas Murray, chief executive officer of Moseda. "We have seen growing demand for mHealth and telemedicine solutions from private and public institutions in order to reliably support remote patient monitoring programs. mHealth and telemedicine technology allow for more efficient, convenient and potentially more cost-effective delivery of care. Offering patients and physicians reliable health devices to perform routine checkups and health assessments remotely is a key factor in determining the long-term success of such programs."

The company is in negotiations with an international pharmaceutical and medical device company to become a reseller of its device in Canada. Pending procurement of devices, the company plans to launch sales in fourth-quarter 2015.

Monday, September 21, 2015

Moseda Technologies (V.MSD) closes $1.2-million placement


Moseda Technologies Inc. has closed the oversubscribed non-brokered private placement of eight million units of Moseda at a price of 15 cents per unit for gross proceeds of $1.2-million.
Each Unit each consists of one (1) common share (the "Common Share") and one half (1/2) transferrable share purchase warrant (the "Warrant"). Each warrant entitles the holder thereof to purchase one (1) additional Common Share on or before September 21, 2016 at a price of CDN$0.25 per Common Share.

In accordance with the policies of the TSX Venture Exchange (the "Exchange"), the Company will pay Finders' Fees.

The securities issued are subject to the statutory 4 month hold period as described by the regulatory authorities.

The Company announces an additional non-brokered financing of 1,500,000 Units at a price of $0.20 per Unit for gross proceeds of $300,000.00. It is expected that this financing will close imminently.

Each Unit will consist of one Common Share in the capital of the Company and one half share purchase warrant. Each full Warrant will entitle the holder to purchase one additional common share in the capital of the Company at a price of $0.26 for a period of 12 months from the closing of the offering.

Tuesday, September 1, 2015

Blueocean launches Pure Polar line of supplements

2015-09-01 11:33 ET - News Release

Mr. Gavin Bogle reports

Blueocean NutraSciences Inc.'s new line of Pure Polar dietary supplements are now available for preordering on-line with product delivery within 30 days. The company's Pure Polar XR Omega 3 tablet product was recently named among top CPG products for innovation and market impact. It is available for a limited time at a low introductory price.

Blueocean's PurePolar shrimp oil products are the world's first Omega-3 oil products from shrimp with 10 times the red (astaxanthin) of comparable krill oil products.


  • One of nature's most powerful antioxidants, and Pure Polar has 10x more than krill oil!
  • Pure Polar is formulated to include high amounts of EPA & DHA.
  • Better bioavailability means better absorption, so you get more natural nutrient power

Astaxanthin is nature’s best ‘singlet oxygen quencher’ by being:

BlueOcean NutraSciences Inc.'s Pure Polar XR Product Named 2015 CPG Editor's Choice Award Finalist by Informa's SupplySide

BlueOcean NutraSciences Inc. (TSX VENTURE:BOC) ("BlueOcean" or the "Company"), a nutraceutical company focused on developing specialty oils and extended release (XR) Omega3 oil tablets from shrimp, fish, krill and algae oil for Health and Wellness markets, is pleased to announce that its new Product Pure Polar XR has been Named Among Top CPG Products for Innovation and Market Impact.
Five consumer packaged goods (CPG) products were selected from hundreds of entries by the SupplySide editorial team for achievements in innovation and market impact in 17 different categories. BlueOcean's Pure Polar XR was named to the short list in the Heart Health category. One winner in each category will be announced at SupplySide West 2015, during the SupplySide CPG Editor's Choice Awards Presentations, set for October 7 and 8, in Las Vegas, Nevada.
"This is a great honor and validation of the efforts we have been making at BlueOcean to bring innovative oils and extended release tablet formulations and ingredients to the supplement markets," said BlueOcean CEO, Gavin Bogle.
For more almost 20 years, SupplySide has helped dietary supplement, food, beverage, personal care and cosmetic professionals find information to explore, discover, innovate and market their next best-selling product.
"In the past few years we've had tremendous success highlighting the products that are coming to market, driven by the innovative ingredients highlighted at SupplySide," said Heather Granato, vice president, content, in Informa's Health & Nutrition Network. "In considering hundreds of products, our team narrowed the field based on the unique positioning and ability to serve consumers with truly cutting-edge products."
Mr. Bogle added, "This achievement was made possible by leveraging our differentiating and patent protected bulk shrimp oil products with drug formulator and JV partner CMAX Technologies Inc. ("CMAX") to create extended release Astaxanthin and Omega3 shrimp oil tablets, now commercially available. In addition, I am pleased to announce that at our August 19, 2015, Annual General Meeting of Shareholders, the shareholders voted to elect Management's slate of Directors including a new addition, Vincent Scalisi.
"Vincent is the founder and CEO of Inbox Fitness, and has over 25 years of experience in fitness and media, including as president of the Weider Publications group that produced Men's Fitness, Muscle & Fitness, FLEX, and Muscle & Fitness Hers magazines; chief marketing officer of Iovate Health Sciences (makers of MuscleTech, Hydroxycut and other top supplement brands), and editor in chief of Muscle & Fitness magazine. Vincent is a fan of all-things-fitness, a patented inventor and industrial design enthusiast."
"I am also pleased to announce the hiring of Brian Wolf as a marketing contractor for BlueOcean. Brian will lead BlueOcean's Tablet and Gelcap marketing efforts. Brian has an extensive history in the supplement industry taking strategic initiatives from start to profitable finish. For more than a decade Brian was the Director of Sales - Vitamin & Health US at Iovate," added Mr. Bogle.
About BlueOceanNutraSciences Inc.
BlueOcean is a Canadian listed public company that is focused on developing sustainable, specialty nutraceutical oil products targeted at the rapidly growing Natural Astaxanthin, Omega3 and Algal oil health and wellness markets.
BlueOcean and its 50% JV partner, CMAX, have developed a process to convert shrimp, krill, algae and other fish oils into Extended Release Tablets.
The natural oils to be used in BlueOcean's products contain high levels of naturally occurring astaxanthin, phospholipids, and omega3 EPA and DHA. AstaShrimp™ will be targeted at the high value and rapidly growing natural astaxanthin market. AlgaOmega™ oil is vegetarian, non-GMO omega3 algal oil containing high levels of EPA with Polar Lipids and is targeted at the rapidly growing omega3 algal oil ingredient market. The extended release tablets target the rapidly growing omega3 consumer market and astaxanthin consumer dietary supplements markets.
Forward Looking Statements
This news release may contain forward-looking statements that are based on BlueOcean's expectations, estimates and projections regarding its business and the economic environment in which it operates. These statements are not guarantees of future performance and involve risks and uncertainties that are difficult to control or predict. Therefore, actual outcomes and results may differ materially from those expressed in these forward-looking statements and readers should not place undue reliance on such statements. Statements speak only as of the date on which they are made, and the Company undertakes no obligation to update them publicly to reflect new information or the occurrence of future events or circumstances, unless otherwise required to do so by law.
Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
To view the images associated with this press release, please visit the following links:
BlueOcean NutraSciences Inc.
Gavin Bogle
BlueOcean NutraSciences Inc.
Dil Vashi
Director of Corporate Development

Thursday, July 16, 2015


Blueocean NutraSciences Inc., effective July 11, 2015, has agreed to buy the Quinlan Brothers Ltd.'s 50-per-cent share of 70717 Newfoundland and Labrador Inc. for a nominal amount. After the close of the transaction, 70717 will become a wholly owned subsidiary of Blueocean. Blueocean and Quinlan agree that the purpose and the underlying economics of the current joint venture structure are not sustainable. Going forward, Blueocean will be free to source North Atlantic shrimp feedstock from multiple sources without restriction for its proprietary North Atlantic shrimp oil products.

Company update

Blueocean is currently marketing shrimp oil sourced from both the North Atlantic and the South Pacific, and has provided numerous samples to interested potential customers.

Blueocean is currently marketing its new sustained-release astaxanthin and omega-3 shrimp oil tablets to supplement companies. In addition, Blueocean has formulated sustained-release omega-3 fish oil tablets and is providing samples to a select group of interested supplement companies.

Blueocean and its joint venture partner, CMAX Technologies Inc., have also developed an omega-3 drink, which the company will begin marketing in third quarter 2015.

The company is still on track to begin bioavailability trials of its sustained-release fish oil tablets during third quarter 2015.
We seek Safe Harbor.

Tuesday, July 14, 2015


Inspira Financial Inc. started trading on the TSX Venture Exchange on July 14, 2015, under the trading symbol LND. Inspira operates in the fragmented marketplace of small companies in the large and growing market for alternative financial services offered to health care providers and their patients across the United States. Inspira is led by seasoned management with experience in both the U.S. healthcare industry and healthcare services asset management. The details of the transaction can be viewed on SEDAR.

Current Operations

Inspira's suite of financial services addresses the needs of small healthcare providers across the U.S. in a market of nearly $1 trillion (according to CMS data). Inspira offers revolving lines of credit ("RLOC") and loans ranging from $250,000 to $12.5 million and is able to generate yields of up to 20% annually. To further enhance growth, Inspira will seek acquisitions of small companies in the growing market for alternative financial services offered to healthcare providers and their patients. Post acquisition, Inspira plans to enhance operational efficiencies and increase revenues through cross-selling a comprehensive suite of alternative finance solutions.

Financial and Business Highlights at Listing:

-- $35 million loan book in approximately 9 months of operation
-- $28 million currently drawn from lending facility at a cost of 5% annual interest to Inspira
-- Operationally profitable and cash flow positive
-- $22.5 million of cash on the balance sheet
-- $24.5 million in potential cash from warrants outstanding
-- Up to a $500 million loan book achievable with no further equity financings, assuming fully- diluted capitalization and 80% leverage
-- Created a proprietary online tool for credit line applications, due diligence and loan management
-- Established several origination channels and has received over 250 applications for loans and lines of credit in 9 months.

"As a public company, we've significantly strengthened our financial position and enter the market at an opportune time," said David Costine, CEO of Inspira. "Inefficiencies resulting from a fragmented market of small loan providers sets the stage for significant growth. At a 5-to-1 debt to equity ratio, we have raised enough equity to build our loan book over $500 million and expect strong returns on this equity."

We seek Safe Harbor.

Wednesday, July 8, 2015


Vanc Pharmaceuticals Inc. has commenced commercialization of its generic drug portfolio in British Columbia and has started shipping initial purchase orders to pharmacy customers.
"We are excited to have launched sales in our home province of B.C. and over the next two quarters we will work towards listing on other provincial formularies which will open up additional markets in our roll-out strategy," said Arun Nayyar, chief executive officer of Vanc. "We look forward to ramping up sales in [third quarter] 2015 and introducing additional products to our customers."

Further to the company's press release from March 12, 2015, the company has received an additional $1,095,728 from warrant and option exercises, bringing the total proceeds from warrant and option exercises during the first two quarters of the calendar year to $3,095,728.
We seek Safe Harbor.

Sunday, June 7, 2015

VANC Pharmaceuticals Announces Appointment of Mr. Bob Rai to its Board of Directors

VANC Pharmaceuticals Inc. (TSX VENTURE:NPH)(OTCQB:NUVPF) ("VANC" or the "Company"), a pharmaceutical company focused on the Canadian generic drug and over-the-counter (the "OTC") markets, is pleased to announce that Mr.Bob Rai has been appointed to the Company's Board of Directors effective immediately. Mr. Rai is a pharmacist with over 15 years of experience and is partner in a chain of The Medicine Shoppe Pharmacy (
"We are excited to have someone with Mr. Rai's industry experience, track record as an entrepreneur and global pedigree join our board. We welcome him to our growing team and eagerly await his input on the strategic direction of our Company," said Arun Nayyar, CEO of VANC. "As we begin the commercialization of our product portfolio it is crucial that our team be optimized and Mr. Rai's direct experience in the Canadian retail and institutional pharmacy business is going to be an immediate value add and impactful addition for the Company."
Mr. Rai is a graduate of the University of British Columbia with Bachelor of Science Degrees in Biochemistry and Pharmaceutical Science. In addition to operating a chain of The Medicine Shoppe Pharmacies in Greater Vancouver for the past 15 years, he has had several successful entrepreneurial and charitable endeavors. In 1998 Mr. Rai and his partners pioneered and revolutionized the online pharmacy business to the United States. The online sales and distribution of prescription medicines saw unprecedented industry growth and as other operators followed suit, the unique business concept became a billion dollar industry across Canada.
Mr. Rai is also Chairman and CEO of Canada Pacific Global Pharmaceuticals and Chairman of its subsidiary, PharmaCanada Inc. ( He has served as President of the Philippines Canada Trade Council (PCTC) from 2006-2007 and held the position of Vice-President from 2004-2006. As President of PCTC, he led a successful Trade Mission to Manila with endorsements from His Excellency Canadian Prime Minister Stephen Harper, Honorable Premier Gordon Campbell of British Columbia and Minister of International Trade and Industry of Canada David Emerson.
In 2013 Mr. Rai was the recipient of the Queen's Diamond Jubilee Medal for his over 18 years of community and volunteer work. His charitable and community volunteer activities include: Alumni UBC Advisory Council representing the Faculty of Pharmaceutical Science, Director of Tapestry Foundation for Health Care, Rotary Club of Vancouver Fraserview and cabinet member of "A Night of Miracles" for BC Children's Hospital.
"I am impressed with how far VANC has come as a startup in a highly competitive industry and commend the existing team for building a product portfolio, registering it with Health Canada and rolling it out commercially in such a cost and time efficient manner. I look forward to working with the team and helping them with governance, technology, product acquisition and accelerating sales," said Mr. Bob Rai.
The Company has also set aside 400,000 incentive stock options at $0.45 for a period of five years and 800,000 incentive stock options at $0.55 for a period of two years to Directors, Officers and Consultants.
On behalf of:
VANC Pharmaceuticals Inc.
Arun Nayar, President & CEO

Tuesday, May 26, 2015

InMed Pharmaceuticals Files Provisional Patent Covering Novel Compounds for Treating Epidermolysis Bullosa Simplex (EBS)

VANCOUVER, British Columbia, May 26, 2015 /PRNewswire/ -- InMed Pharmaceuticals Inc. ("InMed") (CSE: IN; OTCQB: IMLFF), announced today that it has filed a provisional patent application with the United States Patent and Trademark Office ("USPTO") relating to the treatment of Epidermolysis Bullosa Simplex (EBS) using novel formulations of natural cannabinoid compounds developed by InMed.
Dr. Sazzad Hossain, InMed Pharmaceuticals' Chief Scientific Officer, commented, "We are excited to file our first patent covering the use of our products in a high-value orphan disease category. Based on preliminary studies, our compounds are expected to positively address the significant medical needs of EBS by promoting improvement of the key hallmarks of the disease (anti-itching, wound healing, anti-microbial, pain, anti-inflammation). We are continuing the process to build our IP within the dermatology area, adding further value to our pipeline of novel therapeutics."
A provisional patent application is a legal document that establishes an early priority date for the benefit of claiming "first to file" status against other companies or individuals that may want to file for a patent with similar claims after the filing date of our provisional application.
About InMed   
InMed is a clinical stage biopharmaceutical company that specializes in developing cannabis based therapies through the research and development into the extensive pharmacology of cannabinoids coupled with innovative drug delivery systems. InMed's proprietary platform technology, product pipeline and accelerated development pathway are the fundamental value drivers of the Company.

Thursday, May 21, 2015

BlueOcean NutraSciences (V.BOC) Looking for a Hit in the Omega Biz With Shrimp Oil

Peter Epstein, CFA, MBA Twitter: @peterepstein2
The following interview with Gavin Bogle, JD, MBA, MS – CEO & Director of BlueOcean NutraSciences Inc was conducted in the week ended May 22, 2015
Please describe in just one paragraph the BlueOcean NutraSciences Inc story.
BlueOcean’s mission is to develop and commercialize new and innovative dietary supplements and ingredients for dietary supplements from high quality, sustainable sources. Examples are our AstaShrimp™ and AlgaOmega™ oils. BlueOcean will also deliver pharmaceutical-grade dosage forms for dietary supplements. This will be especially helpful for supplements that have poor bioavailability. Our first products are extended release omega-3 fish oil tablets and extended release astaxanthin/omega-3 shrimp oil tablets..
In looking through the Management & Board members, I came across few that have direct experience in selling shrimp, krill or fish oils at the retail or bulk sale levels, why is that?
As the CEO I have extensive C-suite level experience with one of the world’s greatest dietary supplement marketing companies.  Our VP of Marketing has a strong, entrepreneurial background in retail sales including experience in the food industry that is closely aligned with the supplement industry.  Our Board has a variety of strengths in management, financing, and process engineering, all very important skills as we grow.
I was surprised to do a Google search of, “shrimp oil” omega-3 with the majority of hits about BlueOcean’s shrimp oil plans. By comparison, a search for, ‘krill oil’ was overrun with offers to sell, mostly gel caps. Interestingly, there were a number of, “articles” comparing Krill to Fish oil. What do you make of all of this?
Quite simply, there is no omega-3 shrimp oil product on the market. While shrimp extracts are a traditional food in many cultures, the oil has not been systematically extracted for its omega 3s until now. BlueOcean’s shrimp oils are the first, so you won’t find any other companies selling it. The krill oil market has developed over the past decade and is now a maturing, competitive market, though with robust growth.
Krill oil’s main selling point is their phospholipid bound omega-3s that are claimed to make the omega-3s more bioavailable compared to fish oil. Most comparisons between the two oils are based on these bioavailability claims.BlueOcean’s AstaShrimp™ oils will side step the krill oil and fish oil competition by focusing on the high natural astaxanthin. Astaxanthin is a truly, “super” antioxident.  With natural astaxanthin and phospholipid omega-3s our are truly a 2 in 1 offering that has superior qualities on key attributes to current products in both markets.
Playing Devil’s advocate, how can an investor know if the scarcity of news on Shrimp oil is due to problems with it, as opposed to it being a new product? In layman’s terms, what makes Shrimp oil better than Krill oil? Is it a lot better or just marginally better? 
While there have been challenges in producing shrimp oils, those are now behind us. The fact is people eat the shrimp and their oils regularly. It was BlueOcean’s novel idea to use the left overs of the shrimp to make a sustainable supplement. The simple answer is that our shrimp oil is better than krill oil, as it has the same phospholipid bound omega-3s and up to 20 times the amount of natural astaxanthin, which makes it a true 2 in 1 product. You get a full dose of omega-3s and astaxanthin. A search of natural astaxanthin will show you how it is a rapidly growing high-value market.
The scarcity in the news on shrimp oil is simply because no one else had the idea of utilizing this source of raw material for a supplement. The focus has been on phospholipid bound omega-3s and not astaxanthin. Krill oil has a good profile of phospholipid omega-3 and a high oil yield compared to shrimp and is thus cheaper to produce. Now that astaxanthin is a hot product, we will ask a premium price for our shrimp oil. We expect it to be a disruptor in the astaxanthin market, with its omega-3 benefit too.
Are there meaningful sustainability issues with the harvesting of either Krill or Shrimp? (both oils come from waste products?). 
Krill oil is NOT from waste. It is extracted from the whole krill that is caught in the Antarctic Ocean that many believe takes food away from other marine life such as whales. That is the primary negative story surrounding krill and the reason some retailers will not sell krill oil. BlueOcean shrimp oils ARE from shrimp waste and are sustainably sourced. The Canadian source of our shrimp oil is a Marine Stewardship Council certified fishery.
Superior products fighting against strong incumbents can have a difficult time. What is BlueOcean’s plan in this respect? 
We have numerous differentiators and the fact is that new is better in the dietary supplement industry. Since we are targeting primarily the astaxanthin market, and secondarily the omega market, the astaxanthin market is much newer and therefore has fewer strong incumbents.
For the more mature omega-3 market, BlueOcean’s extended release fish oil tablets do not compete with a group of strong incumbents per se, but rather compete with the standard gel cap delivery method. Many of the incumbents in the omega-3 market themselves have identified extended release omega-3 tablets as the market disruptor. These are consumer products markets that demand new and innovative products, which both the shrimp oils and extended release tablets are.
Who will pay the considerable amount of marking dollars to promote and advertise the health and/or cost benefits of Shrimp oil?
We are primarily selling to established marketers of dietary supplements including omega 3 oils. Our customers already have strong marketing and distribution channels. We only need to market to several dozen customers. The benefits of shrimp oil come from the astaxanthin and phospholipid omega-3s. Both of these compounds have had extensive research and marketing already conducted on their benefits, which are easily recognized by our sophisticated customers.
If Shrimp oil supplements or bulk orders to larger companies become successful, how hard and how soon would competing products appear? Are there barriers to entry? 
Shrimp oil production is limited by two things, shrimp waste feedstock and patents. BlueOcean has partnered with and sourced feedstock from Atlantic Canada’s largest processors of shrimp as well as sourced more shrimp feedstock from its Asian partners. BlueOcean has also been granted the exclusive license from Neptune Technologies to sell bulk shrimp oil in North America and Australia as shrimp oil contains the patented phospholipid bound omega-3s, similar to krill. In addition, BlueOcean has filed numerous patents of it’s own. Therefore, with the captive feedstock and intellectual property, BlueOcean has created substantial barriers to entry for shrimp oil in these markets.
Can detractors, perhaps companies tied to Krill, point to any studies, articles, testimonials, etc. suggesting that Shrimp oil is dangerous? 
In a word, NO, any of the arguments against shrimp would apply to the closely related krill as well.
How much of BlueOcean’s own retail product is expected to be on the shelf vs. bulk orders to larger companies who place it into their own formulations? 
BlueOcean’s own retail product lines will be sold online and ultimately would be less than perhaps 5% of the total retail shrimp oil and tablets products that will be sold by our bulk customers.
The logistics of obtaining shrimp waste in western Canada and shipping it to Thailand or India for processing and then back again seem daunting to say the least. Can you explain this process?  
It is not as daunting as it may first appear. For our Northern AstaShrimp oil which is made from Canadian shrimp waste, we basically blast freeze the waste at the shrimp plant, load them on pallets into a reefer, truck it to Halifax where it’s loaded on a ship and sails its way to Vietnam which takes about 2 months. Upon arrival it’s unloaded at the port, taken to the factory and processed into oil. The costs are not too high either. It’s actually cheaper to ship from Canada to Vietnam than Canada to Texas!
Is Krill oil processed the same way, i.e, shipped to Thailand or India? 
Most krill oil is extracted at facilities in the US in plants owned by the krill companies or contract manufactured to plants in China. Finding a good extraction partner is tough, that is why they build their own plants. BlueOcean has found a very good partner and is thus contract manufacturing with this globally recognized extraction partner in Vietnam.
As much as I tried, I can’t avoid asking about bioavailability claims. I recognize this to be an area of ongoing research. For example, better bioavailability could lead to lower doses. Can you address this topic in laypeople’s terms? 
Basically bioavailability refers to how much compound is actually absorbed and used by the body versus the amount that you consume. As with most oily non-water soluble compounds, omega-3s in fish oil have poor bioavailability as they are in triglyceride form. Krill oil has better bioavailability as the omegas are in phospholipid form that is better absorbed by the body.
Our joint venture partner has a history of using its formulating technology to produce high bioavailability drugs of similar oily drugs that typically have poor bioavailability, in an analogous situation to our supplements. In clinical trials we will compare our fish oil tablets to fish oil gel caps in order to prove that our tablets have better bioavailability. We will prove that our fish oil tablets have better bioavailability than fish oil gel caps in clinical trials.
Are there compelling reasons for prospective investors to buy BlueOcean stock sooner rather than later? 
I think the most compelling reason to buy our stock now is that we are currently a pre-revenue company but expect significant revenues in 2015 and expect our share price to react accordingly.
In closing are there any misconceptions about BlueOcean NutraSciences that you would like to address?
Customers regularly ask me when our oils will be available and what development work remains to be done. The answer is none. We can deliver oil in 60 days from orders.